Target Workspace
NaV1.7 / SCN9A
Voltage-gated sodium channel·Moderate-HighImproving·Review recommended·TSTranslational Science· Updated 3 days ago
Evidence pillars
Click a pillar to inspectWhat changed
Confidence moved from Moderate to Moderate-High after new genetic evidence was added to this workspace. Driver: new GWAS replication for chronic neuropathic pain.
Evidence timeline · 24 months
- 3 days agoNew GWAS for chronic neuropathic pain published; replicated SCN9A signal
- 3 months agoSelectivity-strategy paper published in peer-reviewed literature
- 9 months agoPublic competitor program enters Phase I (general field activity)
- 18 months agoField-level review of NaV1.7 chemistry challenges published
Open questions
- Can selectivity vs NaV1.5 / NaV1.4 be achieved in clinic?
- Magnitude of analgesia at safe peripheral exposure?
- Which segment delivers cleanest POC?
Data gaps
- • Internal selectivity data for any candidate molecules (would be customer-internal)
- • Named NaV1.7 competitor compounds held back pending verification
- • Specific patient stratification biomarkers for chronic neuropathic pain
- • Updated competitive intelligence on specific compounds
Next recommended action
Review NaV1.7 patient segments and trial feasibility.Open segments
Activity
- Genetics evidence updated — new GWAS at SCN9A locusSystem · 3d ago
- Feasibility owner added DPN reviewL. Park · 2d ago
- Competitive landscape awaiting source checkSystem · 1d ago
- Assigned NaV1.7 to Translational ScienceM. Reyes · 1d ago